Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2024

Open Access 01-12-2024 | Enalapril | Research

A systematic review and meta-analysis on sodium tanshinone IIA sulfonate injection for the adjunctive therapy of pulmonary heart disease

Authors: Huikai Shao, Fei Yu, Dongsheng Xu, Chunyan Fang, Rongsheng Tong, Lingguo Zhao

Published in: BMC Complementary Medicine and Therapies | Issue 1/2024

Login to get access

Abstract

Aims

Sodium tanshinone IIA sulfonate (STS) injection has been widely used as adjunctive therapy for pulmonary heart disease (PHD) in China. Nevertheless, the efficacy of STS injection has not been systematically evaluated so far. Hence, the efficacy of STS injection as adjunctive therapy for PHD was explored in this study.

Methods

Randomized controlled trials (RCTs) were screened from China Science and Technology Journal Database, China National Knowledge Infrastructure, Wanfang Database, PubMed, Sino-Med, Google Scholar, Medline, Chinese Biomedical Literature Database, Cochrane Library, Embase and Chinese Science Citation Database until 20 January 2024. Literature searching, data collection and quality assessment were independently performed by two investigators. The extracted data was analyzed with RevMan 5.4 and STATA 14.0. Basing on the methodological quality, dosage of STS injection, control group measures and intervention time, sensitivity analysis and subgroup analysis were performed.

Results

19 RCTs with 1739 patients were included in this study. Results showed that as adjunctive therapy, STS injection combined with Western medicine showed better therapeutic efficacy than Western medicine alone for PHD by increasing the clinical effective rate (RR = 1.22; 95% CI, 1.17 to 1.27; p < 0.001), partial pressure of oxygen (MD = 10.16; 95% CI, 5.07 to 15.24; p < 0.001), left ventricular ejection fraction (MD = 8.66; 95% CI, 6.14 to 11.18; p < 0.001) and stroke volume (MD = 13.10; 95% CI, 11.83 to 14.38; p < 0.001), meanwhile decreasing the low shear blood viscosity (MD = -1.16; 95% CI, -1.57 to -0.74; p < 0.001), high shear blood viscosity (MD = -0.64; 95% CI, -0.86 to -0.42; p < 0.001), plasma viscosity (MD = -0.23; 95% CI, -0.30 to -0.17; p < 0.001), hematokrit (MD = -8.52; 95% CI, -11.06 to -5.98; p < 0.001), fibrinogen (MD = -0.62; 95% CI, -0.87 to -0.37; p < 0.001) and partial pressure of carbon dioxide (MD = -8.56; 95% CI, -12.09 to -5.02; p < 0.001).

Conclusion

STS injection as adjunctive therapy seemed to be more effective than Western medicine alone for PHD. However, due to low quality of the included RCTs, more well-designed RCTs were necessary to verify the efficacy of STS injection.
Appendix
Available only for authorised users
Literature
1.
go back to reference Forfia PR, Vaidya A, Wiegers SE. Pulmonary heart disease: the heart-lung interaction and its impact on patient phenotypes. Pulm Circul. 2013;3(1):5–19.CrossRef Forfia PR, Vaidya A, Wiegers SE. Pulmonary heart disease: the heart-lung interaction and its impact on patient phenotypes. Pulm Circul. 2013;3(1):5–19.CrossRef
2.
go back to reference Budev MM, Arroliga AC, Wiedemann HP, Matthay RA. Cor pulmonale: an overview. Semin Respir Crit Care Med. 2003;24(3):233–44.PubMedCrossRef Budev MM, Arroliga AC, Wiedemann HP, Matthay RA. Cor pulmonale: an overview. Semin Respir Crit Care Med. 2003;24(3):233–44.PubMedCrossRef
3.
go back to reference Wang KH, Wu JR, Wang HJ, Duan XJ, Zhang D, Wang YZ, Ni MW, Liu SY, Meng ZQ, Zeng XT, Zhang XM. Comparative efficacy of Chinese herbal injections for pulmonary heart disease: a bayesian network meta-analysis of randomized controlled trials. Front Pharmacol. 2020;11:634.PubMedPubMedCentralCrossRef Wang KH, Wu JR, Wang HJ, Duan XJ, Zhang D, Wang YZ, Ni MW, Liu SY, Meng ZQ, Zeng XT, Zhang XM. Comparative efficacy of Chinese herbal injections for pulmonary heart disease: a bayesian network meta-analysis of randomized controlled trials. Front Pharmacol. 2020;11:634.PubMedPubMedCentralCrossRef
4.
go back to reference Qiu J, Guo YJ, Yue HM, Yang YP. Ginkgo leaf extract and dipyridamole injection for chronic cor pulmonale: a PRISMA-compliant meta-analysis of randomized controlled trials. Bioscience Rep. 2020;40(3):BSR20200099.CrossRef Qiu J, Guo YJ, Yue HM, Yang YP. Ginkgo leaf extract and dipyridamole injection for chronic cor pulmonale: a PRISMA-compliant meta-analysis of randomized controlled trials. Bioscience Rep. 2020;40(3):BSR20200099.CrossRef
5.
go back to reference Liu Y, Huang YH, Zhao CY, Qin XD, Zhu QH, Chen S, Qu JL. Salvia miltiorrhiza injection on pulmonary heart disease: a systematic review and meta-analysis. Am J Chin Med. 2014;42(6):1315–31.PubMedCrossRef Liu Y, Huang YH, Zhao CY, Qin XD, Zhu QH, Chen S, Qu JL. Salvia miltiorrhiza injection on pulmonary heart disease: a systematic review and meta-analysis. Am J Chin Med. 2014;42(6):1315–31.PubMedCrossRef
6.
go back to reference Shi LW, Xie YM, Liao X, Chai Y, Luo YH. Shenmai injection as an adjuvant treatment for chronic cor pulmonale heart failure: a systematic review and meta-analysis of randomized controlled trials. BMC Complem Altern Med. 2015;15:418.CrossRef Shi LW, Xie YM, Liao X, Chai Y, Luo YH. Shenmai injection as an adjuvant treatment for chronic cor pulmonale heart failure: a systematic review and meta-analysis of randomized controlled trials. BMC Complem Altern Med. 2015;15:418.CrossRef
7.
8.
go back to reference Xiong C, Li Y, Zhuang GT, Zeng Y, Wei H, Li CY, Li L, Li L, Fu JJ. Clinical efficacy and safety of Chinese herbal medicine versus placebo for the treatment of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Complement Ther Med. 2021;59:102691.PubMedCrossRef Xiong C, Li Y, Zhuang GT, Zeng Y, Wei H, Li CY, Li L, Li L, Fu JJ. Clinical efficacy and safety of Chinese herbal medicine versus placebo for the treatment of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Complement Ther Med. 2021;59:102691.PubMedCrossRef
9.
go back to reference Li L, Yang DL, Li JH, Niu L, Chen Y, Zhao X, Oduro PK, Wei C, Xu ZP, Wang QL, Li YH. Investigation of cardiovascular protective effect of Shenmai injection by network pharmacology and pharmacological evaluation. BMC Complement Med Ther. 2020;20:112.PubMedPubMedCentralCrossRef Li L, Yang DL, Li JH, Niu L, Chen Y, Zhao X, Oduro PK, Wei C, Xu ZP, Wang QL, Li YH. Investigation of cardiovascular protective effect of Shenmai injection by network pharmacology and pharmacological evaluation. BMC Complement Med Ther. 2020;20:112.PubMedPubMedCentralCrossRef
10.
go back to reference Hong ML, Hong CL, Chen HN, Ke GS, Huang JR, Huang XH, Liu YH, Li FS, Li CD. Effects of the Chinese herb formula yufeining on stable chronic obstructive pulmonary disease. Medicine. 2018;97:39e12461.CrossRef Hong ML, Hong CL, Chen HN, Ke GS, Huang JR, Huang XH, Liu YH, Li FS, Li CD. Effects of the Chinese herb formula yufeining on stable chronic obstructive pulmonary disease. Medicine. 2018;97:39e12461.CrossRef
11.
go back to reference Zhou ZY, Zhao WR, Zhang J, Chen XL, Tang JY. Sodium tanshinone IIA sulfonate: a review of pharmacological activity and pharmacokinetics. Biomed Pharmacother. 2019;118:109362.PubMedCrossRef Zhou ZY, Zhao WR, Zhang J, Chen XL, Tang JY. Sodium tanshinone IIA sulfonate: a review of pharmacological activity and pharmacokinetics. Biomed Pharmacother. 2019;118:109362.PubMedCrossRef
13.
go back to reference Jiang Q, Lu W, Yang K, Hadadi C, Fu X, Chen Y. Sodium tanshinone IIA sulfonate inhibits hypoxia-induced enhancement of SOCE in pulmonary arterial smooth muscle cells via the PKG-PPAR-gamma signaling axis. Am J Physiol Cell Physiol. 2016;311:136–49.CrossRef Jiang Q, Lu W, Yang K, Hadadi C, Fu X, Chen Y. Sodium tanshinone IIA sulfonate inhibits hypoxia-induced enhancement of SOCE in pulmonary arterial smooth muscle cells via the PKG-PPAR-gamma signaling axis. Am J Physiol Cell Physiol. 2016;311:136–49.CrossRef
14.
go back to reference Huang YF, Liu ML, Dong MQ, Yang WC, Zhang B, Luan LL, Dong HY, Xu M, Wang YX, Liu LL, Gao YQ, Li ZC. Effects of sodium tanshinone IIA sulphonate on hypoxic pulmonary hypertension in rats in vivo and on Kv2.1 expression in pulmonary artery smooth muscle cells in vitro. J Ethnopharmacol. 2009;125(3):436–43.PubMedCrossRef Huang YF, Liu ML, Dong MQ, Yang WC, Zhang B, Luan LL, Dong HY, Xu M, Wang YX, Liu LL, Gao YQ, Li ZC. Effects of sodium tanshinone IIA sulphonate on hypoxic pulmonary hypertension in rats in vivo and on Kv2.1 expression in pulmonary artery smooth muscle cells in vitro. J Ethnopharmacol. 2009;125(3):436–43.PubMedCrossRef
15.
go back to reference Wang J, Jiang Q, Wan LM, Yang K, Zhang Y, Chen YQ, Wang E, Lai N, Zhao L, Jiang H, Sun YQ, Zhong NS, Ran PX, Lu WJ. Sodium tanshinone IIA sulfonate inhibits canonical transient receptor potential expression in pulmonary arterial smooth muscle from pulmonary hypertensive rats. Am J Respir Cell Mol Biol. 2013;48:125–34.PubMedPubMedCentralCrossRef Wang J, Jiang Q, Wan LM, Yang K, Zhang Y, Chen YQ, Wang E, Lai N, Zhao L, Jiang H, Sun YQ, Zhong NS, Ran PX, Lu WJ. Sodium tanshinone IIA sulfonate inhibits canonical transient receptor potential expression in pulmonary arterial smooth muscle from pulmonary hypertensive rats. Am J Respir Cell Mol Biol. 2013;48:125–34.PubMedPubMedCentralCrossRef
16.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyzes: the PRISMA Statement. PLoS Med. 2009;6(6):e1000097.PubMedPubMedCentralCrossRef Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyzes: the PRISMA Statement. PLoS Med. 2009;6(6):e1000097.PubMedPubMedCentralCrossRef
17.
go back to reference Shao HK, Huang Y, Xu DS, Huang SF, Tong RS. A systematic review and meta-analysis on the efficacy of puerarin injection as adjunctive therapy for unstable angina pectoris. Front Cardiovasc Med. 2022;9:763567.PubMedPubMedCentralCrossRef Shao HK, Huang Y, Xu DS, Huang SF, Tong RS. A systematic review and meta-analysis on the efficacy of puerarin injection as adjunctive therapy for unstable angina pectoris. Front Cardiovasc Med. 2022;9:763567.PubMedPubMedCentralCrossRef
18.
go back to reference Shao HK, Fang CY, Huang Y, Ye YL, Tong RS. Sodium tanshinone IIA sulfonate injection as adjunctive therapy for the treatment of heart failure: a systematic review and meta-analysis. Phytomedicine. 2022;95:153879.PubMedCrossRef Shao HK, Fang CY, Huang Y, Ye YL, Tong RS. Sodium tanshinone IIA sulfonate injection as adjunctive therapy for the treatment of heart failure: a systematic review and meta-analysis. Phytomedicine. 2022;95:153879.PubMedCrossRef
19.
go back to reference Shao HK, He X, Zhang LJ, Du S, Yi XQ, Cui XJ, Liu XX, Huang SF, Tong RS. Efficacy of ligustrazine injection as adjunctive therapy in treating acute cerebral infarction: a systematic review and meta-analysis. Front Pharmacol. 2021;12:761722.PubMedPubMedCentralCrossRef Shao HK, He X, Zhang LJ, Du S, Yi XQ, Cui XJ, Liu XX, Huang SF, Tong RS. Efficacy of ligustrazine injection as adjunctive therapy in treating acute cerebral infarction: a systematic review and meta-analysis. Front Pharmacol. 2021;12:761722.PubMedPubMedCentralCrossRef
20.
go back to reference Shao HK, Li MS, Chen FC, Chen LH, Jiang ZJ, Zhao LG. The efficacy of Danshen injection as adjunctive therapy in treating angina pectoris: a systematic review and meta-analysis. Heart Lung Circ. 2018;27:433–42.PubMedCrossRef Shao HK, Li MS, Chen FC, Chen LH, Jiang ZJ, Zhao LG. The efficacy of Danshen injection as adjunctive therapy in treating angina pectoris: a systematic review and meta-analysis. Heart Lung Circ. 2018;27:433–42.PubMedCrossRef
21.
go back to reference Shao HK, Zhao LG, Chen FC, Zeng SB, Liu SQ, Li JJ. Efficacy of ligustrazine injection as adjunctive therapy for angina pectoris: a systematic review and meta-analysis. Med Sci Monit. 2015;21:3704–15.PubMedPubMedCentralCrossRef Shao HK, Zhao LG, Chen FC, Zeng SB, Liu SQ, Li JJ. Efficacy of ligustrazine injection as adjunctive therapy for angina pectoris: a systematic review and meta-analysis. Med Sci Monit. 2015;21:3704–15.PubMedPubMedCentralCrossRef
22.
go back to reference Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials. 1996;17:1–12.PubMedCrossRef Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials. 1996;17:1–12.PubMedCrossRef
23.
go back to reference Wang KH, Wu JR, Zhang D, Duan XJ, Ni MW. Comparative efficacy of Chinese herbal injections for treating chronic heart failure: a network meta-analysis. BMC Complement Med Ther. 2018;18:41.CrossRef Wang KH, Wu JR, Zhang D, Duan XJ, Ni MW. Comparative efficacy of Chinese herbal injections for treating chronic heart failure: a network meta-analysis. BMC Complement Med Ther. 2018;18:41.CrossRef
24.
go back to reference Lin HY, Wan MY, Ye Y, Zheng GH. Effects of Baduanjin exercise on the physical function of middle-aged and elderly people: a systematic review and meta-analysis of randomized controlled trials. BMC Complement Med Ther. 2020;23:38.CrossRef Lin HY, Wan MY, Ye Y, Zheng GH. Effects of Baduanjin exercise on the physical function of middle-aged and elderly people: a systematic review and meta-analysis of randomized controlled trials. BMC Complement Med Ther. 2020;23:38.CrossRef
25.
go back to reference Chai YQ, Wu YM. Clinical observation of Tanshinone IIA sulfonate sodium injection combined with phentolamine in treatment of acute exacerbation of pulmonary heart disease. Drugs Clin. 2017;32(11):2124–8. (In Chinese). Chai YQ, Wu YM. Clinical observation of Tanshinone IIA sulfonate sodium injection combined with phentolamine in treatment of acute exacerbation of pulmonary heart disease. Drugs Clin. 2017;32(11):2124–8. (In Chinese).
26.
go back to reference Cheng KF. Clinical observation of 60 cases of chronic pulmonary heart disease with heart failure treated by sodium nitroprusside combined with sodium tanshinone IIA sulfonate. J Clin Med. 2017;4(12):2355–7. (In Chinese). Cheng KF. Clinical observation of 60 cases of chronic pulmonary heart disease with heart failure treated by sodium nitroprusside combined with sodium tanshinone IIA sulfonate. J Clin Med. 2017;4(12):2355–7. (In Chinese).
27.
go back to reference Chen JX. Clinical observation of enalapril combined with tanshinone in the treatment of acute exacerbation of pulmonary heart disease. Jilin Med. 2016;37(6):1461–2. (In Chinese). Chen JX. Clinical observation of enalapril combined with tanshinone in the treatment of acute exacerbation of pulmonary heart disease. Jilin Med. 2016;37(6):1461–2. (In Chinese).
28.
go back to reference Chen SX. Enalapril and tanshinone on acute exacerbation of clinical curative effect and prognosis of patients with pulmonary heart disease. Mod Diagn Treat. 2015;26(17):3843–5. (In Chinese). Chen SX. Enalapril and tanshinone on acute exacerbation of clinical curative effect and prognosis of patients with pulmonary heart disease. Mod Diagn Treat. 2015;26(17):3843–5. (In Chinese).
29.
go back to reference Liang ZC. The effect of enalapril and tanshinon on hemorheological and cardiac function of patients with acute exacerbation of chronic pulmonary heart disease. Clin J Chin Med. 2016;8(18):114–6. (In Chinese). Liang ZC. The effect of enalapril and tanshinon on hemorheological and cardiac function of patients with acute exacerbation of chronic pulmonary heart disease. Clin J Chin Med. 2016;8(18):114–6. (In Chinese).
30.
go back to reference Lin JY, Deng YB, Xiao SR, Xu GD, Luo WG, Jiang YJ. An observation of clinical efficacy of combined treatment of enalapril and tanshinon on pulmonary heart disease during acute exacerbation. Chin Youjiang Med J. 2016;44(6):614–7. (In Chinese). Lin JY, Deng YB, Xiao SR, Xu GD, Luo WG, Jiang YJ. An observation of clinical efficacy of combined treatment of enalapril and tanshinon on pulmonary heart disease during acute exacerbation. Chin Youjiang Med J. 2016;44(6):614–7. (In Chinese).
31.
go back to reference Li SY. Clinical observation of etapril combined with tanshinone in the treatment of acute exacerbation of pulmonary heart disease. Jiangxi Med J. 2014;49(9):858–60. (In Chinese). Li SY. Clinical observation of etapril combined with tanshinone in the treatment of acute exacerbation of pulmonary heart disease. Jiangxi Med J. 2014;49(9):858–60. (In Chinese).
32.
go back to reference Liu JL, Shang XX, Wang CB, Tang Y, Yang LC. Investigating the clinical effect of enalapril combined with tanshinone in the treatment of acute exacerbation of pulmonary heart disease. China Health Care Nutr. 2017;27(29):126–7. (In Chinese). Liu JL, Shang XX, Wang CB, Tang Y, Yang LC. Investigating the clinical effect of enalapril combined with tanshinone in the treatment of acute exacerbation of pulmonary heart disease. China Health Care Nutr. 2017;27(29):126–7. (In Chinese).
33.
go back to reference Lu CB, Zhou ZJ. Efficacy and safety of etapril combined with tanshinone in the treatment of acute exacerbation of pulmonary heart disease. Chin J Mod Drug Appl. 2014;8(1):181–2. (In Chinese). Lu CB, Zhou ZJ. Efficacy and safety of etapril combined with tanshinone in the treatment of acute exacerbation of pulmonary heart disease. Chin J Mod Drug Appl. 2014;8(1):181–2. (In Chinese).
34.
go back to reference Lu P. Clinical observation of adenosine cyclophosphor meglamine combined with tanshinone sodium IIA sulfonate in pulmonary heart disease. J Med Theor Prac. 2017;30(24):3634–6. (In Chinese). Lu P. Clinical observation of adenosine cyclophosphor meglamine combined with tanshinone sodium IIA sulfonate in pulmonary heart disease. J Med Theor Prac. 2017;30(24):3634–6. (In Chinese).
35.
go back to reference Ma Y. Enalapril combined with tanshinone treatment of pulmonary heart disease in acute exacerbation of observation. Cardiovasc Dis J Integr Tradit Chin Western Med. 2015;3(10):124–5. (In Chinese). Ma Y. Enalapril combined with tanshinone treatment of pulmonary heart disease in acute exacerbation of observation. Cardiovasc Dis J Integr Tradit Chin Western Med. 2015;3(10):124–5. (In Chinese).
36.
go back to reference Mei WH. Clinical observation of enalapril combined with tanshinone in acute exacerbation of pulmonary heart disease. Womens Health Res. 2018;5:2. (In Chinese). Mei WH. Clinical observation of enalapril combined with tanshinone in acute exacerbation of pulmonary heart disease. Womens Health Res. 2018;5:2. (In Chinese).
37.
go back to reference Ni F. Clinical study on sodium tanshinone IIA sulfonate combined with phentolamine in the treatment of 55 patients with acute exacerbation phase of pulmonary heart disease. China Pharm. 2018;27(20):44–6. (In Chinese). Ni F. Clinical study on sodium tanshinone IIA sulfonate combined with phentolamine in the treatment of 55 patients with acute exacerbation phase of pulmonary heart disease. China Pharm. 2018;27(20):44–6. (In Chinese).
38.
go back to reference Song HH, Deng GS, Li G. Analysis of improvement of enalapril and tanshinone for blood rheology and cardiac function in patients with acute exacerbation of pulmonary heart disease. J Clin Pulm Med. 2017;22(6):1078–81. (In Chinese). Song HH, Deng GS, Li G. Analysis of improvement of enalapril and tanshinone for blood rheology and cardiac function in patients with acute exacerbation of pulmonary heart disease. J Clin Pulm Med. 2017;22(6):1078–81. (In Chinese).
39.
go back to reference Wang W. Clinical effect of enalapril combined with tanshinone in the treatment of acute exacerbation of cor pulmonale. Heilongjiang Med J. 2021;34(3):588–90. (In Chinese). Wang W. Clinical effect of enalapril combined with tanshinone in the treatment of acute exacerbation of cor pulmonale. Heilongjiang Med J. 2021;34(3):588–90. (In Chinese).
40.
go back to reference Wang XQ. Study on the effect of enalapril combined with tanshinone and improvement of cardiac function in patients with acute exacerbation of pulmonary heart disease. Clin Res. 2019;27(3):93–5. (In Chinese). Wang XQ. Study on the effect of enalapril combined with tanshinone and improvement of cardiac function in patients with acute exacerbation of pulmonary heart disease. Clin Res. 2019;27(3):93–5. (In Chinese).
41.
go back to reference Wang XR, Zhao S. The effects of tanshinone IIA sulfonate on hemorheology and blood lipid in patients with pulmonary heart disease. Chin J Biochem Pharm. 2011;32(3):237–8. (In Chinese). Wang XR, Zhao S. The effects of tanshinone IIA sulfonate on hemorheology and blood lipid in patients with pulmonary heart disease. Chin J Biochem Pharm. 2011;32(3):237–8. (In Chinese).
42.
go back to reference Yang YQ. Curative effect of enazepril and tanshinone in treatment of acute exacerbation of chronic pulmonary heart disease. Chin J Exp Tradit Med Formulae. 2012;18(10):292–4. (In Chinese). Yang YQ. Curative effect of enazepril and tanshinone in treatment of acute exacerbation of chronic pulmonary heart disease. Chin J Exp Tradit Med Formulae. 2012;18(10):292–4. (In Chinese).
43.
go back to reference Zhang J, He CB, Wang SW. Clinical Observation of sulfotanshinone sodium injection combined with alprostadil and sildenafil in treatment of patients with chronic pulmonary heart disease associated by pulmonary hypertension. Med Pharm J Chin PLA. 2018;30(1):71–3. (In Chinese). Zhang J, He CB, Wang SW. Clinical Observation of sulfotanshinone sodium injection combined with alprostadil and sildenafil in treatment of patients with chronic pulmonary heart disease associated by pulmonary hypertension. Med Pharm J Chin PLA. 2018;30(1):71–3. (In Chinese).
44.
go back to reference Li JS, Wang HF, Bai YP, Li SY, Yu XQ, Li Y. Ligustrazine injection for chronic pulmonary heart disease: a systematic review and meta-analysis. Evid Based Compl Alt. 2012; 2012: 792726. Li JS, Wang HF, Bai YP, Li SY, Yu XQ, Li Y. Ligustrazine injection for chronic pulmonary heart disease: a systematic review and meta-analysis. Evid Based Compl Alt. 2012; 2012: 792726.
45.
go back to reference Li JS, Wang HF, Li SY, Yu XQ, Wang ZW. Shenmai injection for chronic pulmonary heart disease: a systematic review and meta-analysis. J Altern Complem Med. 2011;17(7):579–87.CrossRef Li JS, Wang HF, Li SY, Yu XQ, Wang ZW. Shenmai injection for chronic pulmonary heart disease: a systematic review and meta-analysis. J Altern Complem Med. 2011;17(7):579–87.CrossRef
46.
go back to reference Guan R, Wang J, Li Z, Ding M, Li D, Xu G, Wang T, Chen Y, Yang Q, Long Z, Cai Z, Zhang C, Liang X, Dong L, Zhao L, Zhang H, Sun D, Lu W. Sodium tanshinone IIA sulfonate decreases cigarette smoke-induced inflammation and oxidative stress via blocking the activation of MAPK/HIF-1alpha signaling pathway. Front Pharmacol. 2018;9:263.PubMedPubMedCentralCrossRef Guan R, Wang J, Li Z, Ding M, Li D, Xu G, Wang T, Chen Y, Yang Q, Long Z, Cai Z, Zhang C, Liang X, Dong L, Zhao L, Zhang H, Sun D, Lu W. Sodium tanshinone IIA sulfonate decreases cigarette smoke-induced inflammation and oxidative stress via blocking the activation of MAPK/HIF-1alpha signaling pathway. Front Pharmacol. 2018;9:263.PubMedPubMedCentralCrossRef
47.
go back to reference Chen PX, Zhang YL, Xu JW, Yu MH, Huang JH, Zhao L, Zhou WL. Sodium tanshinone IIA sulfonate stimulated Cl– secretion in mouse trachea. PLoS ONE. 2017;12(5):e0178226.PubMedPubMedCentralCrossRef Chen PX, Zhang YL, Xu JW, Yu MH, Huang JH, Zhao L, Zhou WL. Sodium tanshinone IIA sulfonate stimulated Cl secretion in mouse trachea. PLoS ONE. 2017;12(5):e0178226.PubMedPubMedCentralCrossRef
Metadata
Title
A systematic review and meta-analysis on sodium tanshinone IIA sulfonate injection for the adjunctive therapy of pulmonary heart disease
Authors
Huikai Shao
Fei Yu
Dongsheng Xu
Chunyan Fang
Rongsheng Tong
Lingguo Zhao
Publication date
01-12-2024
Publisher
BioMed Central
Keyword
Enalapril
Published in
BMC Complementary Medicine and Therapies / Issue 1/2024
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-024-04434-0

Other articles of this Issue 1/2024

BMC Complementary Medicine and Therapies 1/2024 Go to the issue